Guinness Asset Management LTD Has $32.44 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Guinness Asset Management LTD trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 13.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 230,699 shares of the company’s stock after selling 36,280 shares during the quarter. Johnson & Johnson comprises about 3.8% of Guinness Asset Management LTD’s portfolio, making the stock its 13th biggest position. Guinness Asset Management LTD’s holdings in Johnson & Johnson were worth $32,443,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Altshuler Shaham Ltd acquired a new position in Johnson & Johnson during the 1st quarter worth approximately $35,000. Lake Point Wealth Management raised its stake in Johnson & Johnson by 144.4% during the 1st quarter. Lake Point Wealth Management now owns 286 shares of the company’s stock worth $38,000 after buying an additional 169 shares during the period. SeaBridge Investment Advisors LLC raised its stake in Johnson & Johnson by 160.0% during the 2nd quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock worth $46,000 after buying an additional 200 shares during the period. Lion Street Advisors LLC acquired a new position in Johnson & Johnson during the 1st quarter worth approximately $45,000. Finally, Joseph P. Lucia & Associates LLC raised its stake in Johnson & Johnson by 50.8% during the 1st quarter. Joseph P. Lucia & Associates LLC now owns 374 shares of the company’s stock worth $49,000 after buying an additional 126 shares during the period. 68.44% of the stock is currently owned by institutional investors.

In other Johnson & Johnson news, EVP Ashley Mcevoy sold 29,000 shares of the stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the completion of the transaction, the executive vice president now directly owns 21,682 shares of the company’s stock, valued at $3,197,444.54. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.27% of the stock is currently owned by corporate insiders.

A number of research firms recently weighed in on JNJ. Stifel Nicolaus upped their price target on Johnson & Johnson from $140.00 to $155.00 and gave the stock a “hold” rating in a research note on Wednesday, April 15th. Barclays increased their price objective on Johnson & Johnson from $173.00 to $182.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 29th. Wells Fargo & Co raised Johnson & Johnson to a “hold” rating in a research note on Wednesday, April 22nd. Independent Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and increased their price objective for the stock from $161.00 to $164.00 in a research note on Monday, July 20th. Finally, Raymond James increased their price objective on Johnson & Johnson from $157.00 to $158.00 and gave the stock an “outperform” rating in a research note on Friday, July 17th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and twelve have assigned a buy rating to the company. Johnson & Johnson has an average rating of “Buy” and a consensus price target of $163.38.

JNJ stock opened at $145.76 on Friday. The firm has a market cap of $383.76 billion, a PE ratio of 21.31, a P/E/G ratio of 3.23 and a beta of 0.69. The company has a quick ratio of 1.05, a current ratio of 1.25 and a debt-to-equity ratio of 0.40. The business has a 50 day moving average of $144.04 and a 200-day moving average of $144.14. Johnson & Johnson has a 12-month low of $109.16 and a 12-month high of $157.00.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Thursday, July 16th. The company reported $1.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.17. The company had revenue of $18.34 billion during the quarter, compared to analyst estimates of $17.73 billion. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. Johnson & Johnson’s quarterly revenue was down 10.8% on a year-over-year basis. During the same period in the prior year, the company posted $2.58 earnings per share. On average, research analysts expect that Johnson & Johnson will post 7.85 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be issued a $1.01 dividend. This represents a $4.04 annualized dividend and a dividend yield of 2.77%. The ex-dividend date is Monday, August 24th. Johnson & Johnson’s dividend payout ratio is presently 46.54%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Why are analyst ratings important in trading stocks?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.